
Balaxi (BALAXI) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
762.7M
Gross Profit
367.1M
48.13%
Operating Income
120.9M
15.85%
Net Income
86.4M
11.33%
Balance Sheet Metrics
Total Assets
3.1B
Total Liabilities
786.1M
Shareholders Equity
2.3B
Debt to Equity
0.34
Cash Flow Metrics
Revenue & Profitability Trend
Balaxi Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 2.9B | 2.4B | 3.4B | 2.8B | 2.3B |
Cost of Goods Sold | 1.7B | 1.3B | 2.0B | 2.0B | 1.7B |
Gross Profit | 1.3B | 1.1B | 1.3B | 837.9M | 591.9M |
Gross Margin % | 43.4% | 46.7% | 39.8% | 30.0% | 25.6% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 549.1M | 284.5M | 321.0M | 141.6M | 56.6M |
Other Operating Expenses | - | 2.1M | 47.5M | 23.7M | 6.5M |
Total Operating Expenses | 549.1M | 286.6M | 368.5M | 165.3M | 63.1M |
Operating Income | 353.2M | 457.9M | 556.6M | 503.1M | 424.2M |
Operating Margin % | 12.1% | 19.0% | 16.5% | 18.0% | 18.3% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | 18.0K |
Interest Expense | 29.3M | 16.8M | 5.0M | 1.4M | 184.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 286.7M | 20.2M | 569.2M | 545.2M | 443.3M |
Income Tax | 36.0M | 44.0M | 109.6M | 68.6M | 61.9M |
Effective Tax Rate % | 12.6% | 218.4% | 19.3% | 12.6% | 14.0% |
Net Income | 250.7M | -23.9M | 459.6M | 476.6M | 381.4M |
Net Margin % | 8.6% | -1.0% | 13.7% | 17.1% | 16.5% |
Key Metrics | |||||
EBITDA | 335.0M | 441.5M | 591.7M | 551.8M | 446.8M |
EPS (Basic) | - | ₹-0.46 | ₹9.16 | ₹9.53 | ₹7.63 |
EPS (Diluted) | - | ₹-0.46 | ₹9.08 | ₹9.53 | ₹7.63 |
Basic Shares Outstanding | - | 51470130 | 50167000 | 50000000 | 50000000 |
Diluted Shares Outstanding | - | 51470130 | 50167000 | 50000000 | 50000000 |
Income Statement Trend
Balaxi Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 394.0M | 622.9M | 282.2M | 71.9M | 16.7M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.1B | 557.1M | 522.8M | 275.6M | 761.4M |
Inventory | 784.8M | 821.7M | 1.1B | 987.0M | 136.2M |
Other Current Assets | 109.8M | 81.1M | 52.0M | 277.0K | 533.0K |
Total Current Assets | 2.4B | 2.1B | 1.9B | 1.4B | 937.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 142.4M | 57.3M | 59.1M | 54.6M | -13.0K |
Goodwill | 534.9M | 529.8M | 513.6M | 474.3M | 25.6M |
Intangible Assets | - | 7.8M | 9.1M | 8.2M | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 45.2M | 49.8M | 19.2M | 16.7M | - |
Total Non-Current Assets | 675.8M | 481.7M | 461.6M | 354.7M | 59.1M |
Total Assets | 3.1B | 2.6B | 2.4B | 1.8B | 996.8M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 161.8M | 290.4M | 345.2M | 491.1M | 220.6M |
Short-term Debt | 303.8M | 176.6M | 107.5M | 36.4M | 36.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 46.1M | 9.3M | 8.4M | 865.0K | 1.3M |
Total Current Liabilities | 545.3M | 542.0M | 531.3M | 632.7M | 346.9M |
Non-Current Liabilities | |||||
Long-term Debt | 230.5M | 17.4M | 25.6M | 0 | 0 |
Deferred Tax Liabilities | 9.0M | 10.0M | 11.0M | 388.0K | 71.0K |
Other Non-Current Liabilities | - | 1.0K | -1.0K | 1.0K | -4.0K |
Total Non-Current Liabilities | 240.7M | 27.8M | 36.6M | 389.0K | 67.0K |
Total Liabilities | 786.1M | 569.8M | 567.9M | 633.1M | 347.0M |
Equity | |||||
Common Stock | 110.4M | 109.0M | 101.8M | 100.0M | 100.0M |
Retained Earnings | - | 1.4B | 1.4B | 918.6M | 436.8M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.3B | 2.0B | 1.8B | 1.1B | 649.8M |
Key Metrics | |||||
Total Debt | 534.3M | 194.0M | 133.1M | 36.4M | 36.6M |
Working Capital | 1.9B | 1.6B | 1.4B | 777.4M | 590.8M |
Balance Sheet Composition
Balaxi Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 286.7M | 20.2M | 569.2M | 545.2M | 443.3M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -538.2M | 164.1M | -311.1M | -416.4M | -604.3M |
Operating Cash Flow | -196.2M | 151.8M | 320.9M | 135.5M | -169.9M |
Investing Activities | |||||
Capital Expenditures | -211.2M | -1.7M | -108.0M | -47.5M | -12.8M |
Acquisitions | - | - | - | - | - |
Investment Purchases | 0 | 0 | 0 | - | -34.2M |
Investment Sales | 0 | 0 | 0 | 34.2M | 0 |
Investing Cash Flow | -211.2M | -1.7M | -108.5M | -13.8M | -46.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | -5.0M | - | - |
Debt Issuance | 339.6M | 60.4M | 79.8M | - | 36.6M |
Debt Repayment | - | - | - | -211.0K | 0 |
Financing Cash Flow | 367.5M | 318.7M | 259.6M | -212.0K | 36.6M |
Free Cash Flow | -567.7M | 33.0M | -89.0M | 68.0M | -25.5M |
Net Change in Cash | -39.9M | 468.9M | 472.0M | 121.4M | -180.3M |
Cash Flow Trend
Balaxi Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
10.51
Price to Book
1.14
Price to Sales
1.01
Profitability Ratios
Profit Margin
-0.99%
Operating Margin
21.39%
Return on Equity
-1.24%
Return on Assets
11.20%
Financial Health
Current Ratio
3.88
Debt to Equity
9.64
Beta
0.59
Per Share Data
EPS (TTM)
₹4.54
Book Value per Share
₹41.98
Revenue per Share
₹46.91
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
balaxi | 2.4B | 10.51 | 1.14 | -1.24% | -0.99% | 9.64 |
Biocon | 479.6B | 112.27 | 1.99 | 3.66% | 2.44% | 66.26 |
OneSource Specialty | 215.4B | -1,151.60 | 3.65 | -0.31% | -0.85% | 16.03 |
Dishman Carbogen | 42.0B | 1,274.29 | 0.72 | 0.06% | 3.60% | 40.97 |
Zota Health Care | 35.4B | -66.66 | 22.82 | -24.83% | -20.55% | 65.72 |
Panacea Biotec | 25.8B | 91.93 | 3.07 | -1.05% | -1.50% | 2.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.